Innovation and Patent Law Reform: Hearings Before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, Ninety-eighth Congress, Second Session, on H.R. 3285, H.R. 3286, and H.R. 3605 Innovation and Patent Law Reform, March 28, April 26, and June 6, 27, 1984, 2. daļaU.S. Government Printing Office, 1985 - 2897 lappuses |
No grāmatas satura
1.–5. rezultāts no 100.
950. lappuse
... regulatory delay . It is well - known that the impetus for patent term extension legislation came from the research intensive drug companies through the lobbying activities of the Pharmaceutical Manufacturers Association . PMA produced ...
... regulatory delay . It is well - known that the impetus for patent term extension legislation came from the research intensive drug companies through the lobbying activities of the Pharmaceutical Manufacturers Association . PMA produced ...
951. lappuse
... regulatory delays encountered by generic drug makers in bringing products to the market , the effective commercial monopoly life for the 50 top selling drugs turned out to be 15.5 years and for the 100 top selling drugs it was almost 14 ...
... regulatory delays encountered by generic drug makers in bringing products to the market , the effective commercial monopoly life for the 50 top selling drugs turned out to be 15.5 years and for the 100 top selling drugs it was almost 14 ...
952. lappuse
... regulatory delay but is unwilling to give generic companies the same relief from the same problem at the end of the patent monopoly period . Finally , it should be noted that throughout the course of the many hearings which have been ...
... regulatory delay but is unwilling to give generic companies the same relief from the same problem at the end of the patent monopoly period . Finally , it should be noted that throughout the course of the many hearings which have been ...
953. lappuse
... regulatory review period are set forth above . 2 . The patent for which this extension is sought has never been ... Regulations , $ 1.56 ( a ) . I hereby declare that all statements made herein of my own knowledge are true and that all ...
... regulatory review period are set forth above . 2 . The patent for which this extension is sought has never been ... Regulations , $ 1.56 ( a ) . I hereby declare that all statements made herein of my own knowledge are true and that all ...
985. lappuse
... regulatory review for innovative drug products ; and ( 2 ) Accelerates the availability of safe and effective ... regulations for drugs approved before 1962 , the bill precludes FDA from requesting information from an ANDA applicant ...
... regulatory review for innovative drug products ; and ( 2 ) Accelerates the availability of safe and effective ... regulations for drugs approved before 1962 , the bill precludes FDA from requesting information from an ANDA applicant ...
Saturs
946 | |
1095 | |
1118 | |
1134 | |
1140 | |
1142 | |
1145 | |
1183 | |
1577 | |
1612 | |
1626 | |
1656 | |
1660 | |
1663 | |
1672 | |
1680 | |
1206 | |
1215 | |
1245 | |
1284 | |
1294 | |
1307 | |
1335 | |
1339 | |
1360 | |
1435 | |
1482 | |
1725 | |
1739 | |
1756 | |
1824 | |
1835 | |
1855 | |
1867 | |
1871 | |
1886 | |
1888 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
103 prior art 1962 Amendments 2d Cir Adkins ANDA antitrust Appeals available as prior Bass beta blockers bill Bolar challenge successful challenged the validity Circuit claims Clemens clinical testing company/client Consent Judgment contract Corp costs Court decision decision or settlement decline defendant Dextrose diazepam disclosed disclosure district court effective patent electrolyte federal patent filed firms flurazepam grant Hoffmann-La Roche I.V. Solution impact industry Injection innovation invalid inventor Labs Lear doctrine legislation licensee estoppel licensor litigation manufacture ment monopoly NAME TRADE NAME NCEs NDAS APPROVED patent application patent infringement patent law Patent Office patent protection patent system patent term restoration patent validity period pharmaceutical plaintiff preliminary injunction prior art prior invention question reduced to practice regulation regulatory Roche royalties Section 103 prior Sodium Sodium Chloride statutory Stiffel subject matter Supp supra note Tablet tion trade secret Travenol United unpatented USPQ
Populāri fragmenti
1471. lappuse - A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.
1724. lappuse - The economic philosophy behind the clause empowering Congress to grant patents and copyrights is the conviction that encouragement of individual effort by personal gain is the best way to advance public welfare through the talents of authors and inventors in "Science and useful Arts.
1138. lappuse - ... described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or b. the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or c.
1285. lappuse - The several courts vested with jurisdiction of cases arising under the patent laws shall have power to grant injunctions according to the course and principles of courts of equity, to prevent the violation of any right secured by patent, on such terms as the court may deem reasonable...
1412. lappuse - A person shall be entitled to a patent unless: a. the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or b.
1722. lappuse - The utility of this power will scarcely be questioned. The copyright of authors has been solemnly adjudged, in Great Britain, to be a right of common law. The right to useful inventions seems with equal reason to belong to the inventors. The public good fully coincides in both cases with the claims of individuals.
1437. lappuse - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
1412. lappuse - States, or (c) he has abandoned the invention, or (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States...
1380. lappuse - In any action for infringement the defendant may plead the general issue, and having given notice in writing to the plaintiff or his attorney thirty days before, may prove on trial any one or more of the following special matters: First.
1498. lappuse - A trade secret may consist of any formula, pattern, device or compilation of information which is used in one's business, and which gives him an opportunity to obtain an advantage over competitors who do not know or use it.